SK Pharmteco Acquires Controlling Interest in Center for Breakthrough Medicines

SK Pharmteco Acquires Controlling Interest in Center for Breakthrough Medicines

SK Pharmteco, a division of South Korean conglomerate SK Inc., has acquired a controlling interest in the Center for Breakthrough Medicines.  The Center for Breakthrough Medicines is a King of Prussia, Pennsylvania-based contract development and manufacturing organization (CDMO) specializing in cell and gene therapy.  SK Pharmteco is based in Rancho Cordova, California. The company specializes in the production of active pharmaceutical ingredients, advanced intermediates and cell and gene therapy for the pharmaceutical industry.  SK Inc., the investment arm of SK Group in Seoul, previously invested $350 million in the Center for Breakthrough Medicines in December 2021. The... Read More »

Aziyo Biologics Buys CorMatrix Assets

Aziyo Biologics, Inc. is finally gaining some traction. The company was formed in November 2015 by HighCape Partners, a growth equity fund focused on commercial-stage life sciences companies. Deerfield Management Co. joined HighCape in providing capital for the transaction. Aziyo develops customized tissue products for use in orthopedic, spinal, sports medicine, and dermal applications. On May 31, 2017, the company announced the completion of an asset purchase agreement with CorMatrix® Cardiovascular, Inc. for the purchase of all CorMatrix commercial assets and related intellectual property. CorMatrix develops biomaterial devices that harness the body’s own innate... Read More »